论文部分内容阅读
目的探讨表皮生长因子受体(EGFR)表达与鼻咽癌患者治疗后肿瘤残留情况的关系及疗效预测价值。方法 260例鼻咽癌患者应用免疫组织化学技术检测EGFR在癌组织中的表达,并分析肿瘤残留及5年生存情况。结果 EGFR在260例鼻咽癌中阳性表达197例(75.8%),阴性表达63例(24.2%);EGFR阳性组和阴性组放射治疗后肿瘤残留率分别为24.9%、14.3%(χ2=3.61,P<0.05);两组5年总生存率(OS)、无瘤生存率(DFS)、无区域复发生存率(LRFS)、无远处转移生存率(DMFS)分别为68.2%、63.1%,67.2%、64.8%和88.6%、76.4%、87.1%、81.3%(χ2=4.12,χ2=4.01,χ2=3.97,χ2=3.85,P<0.05);有残留者远处转移率67.2%明显高于无残留者17.8%(χ2=7.48,P<0.05);在多因素分析中,EGFR阳性表达与总生存率(OS)和无病生存率(DFS)显著相关(r=6.725,P<0.05);结论EGFR在鼻咽癌中表达率较高,阳性表达与放疗后肿瘤残留存在相关性,并呈现不良预后的趋势,有利于预测鼻咽癌患者放疗前放射敏感性,有助于选择合适患者优化个体化治疗方案。
Objective To investigate the relationship between the expression of epidermal growth factor receptor (EGFR) and the residual tumor in patients with nasopharyngeal carcinoma (NPC) after treatment and the predictive value of the therapeutic effect. Methods 260 cases of nasopharyngeal carcinoma patients with immunohistochemistry detection of EGFR in cancer tissue expression, and analysis of tumor residual and 5-year survival. Results The positive expression rates of EGFR in 260 cases of nasopharyngeal carcinoma were 197 (75.8%) and 63 (24.2%), respectively. The residual rates of EGFR positive group and negative group were 24.9% and 14.3% (χ2 = 3.61 , P <0.05). The 5-year overall OS, DFS, LRFS and DMFS were respectively 68.2%, 63.1% , 67.2%, 64.8% and 88.6%, 76.4%, 87.1% and 81.3%, respectively (χ2 = 4.12, χ2 = 4.01, χ2 = 3.97, χ2 = 3.85, P < (Χ2 = 7.48, P <0.05). In multivariate analysis, the positive expression of EGFR was significantly associated with OS and DFS (r = 6.725, P < 0.05). CONCLUSION: EGFR is highly expressed in nasopharyngeal carcinoma. The positive expression of EGFR correlates with the residual tumor after radiotherapy. It shows a tendency of poor prognosis, which is helpful to predict the radiosensitivity of patients with nasopharyngeal carcinoma before radiotherapy, The right patient to optimize individualized treatment options.